Amivantamab Pregnancy and Breastfeeding Warnings

Brand names: Rybrevant

Medically reviewed by Drugs.com. Last updated on Jun 8, 2023.

Amivantamab Pregnancy Warnings

This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus.

AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned

Risk summary: Based on its mechanism of action and findings in animal models, this drug can cause fetal harm when administered during pregnancy; no data available on use of this drug in pregnant women to inform a drug-related risk.

Comments:
-Pregnancy status of patients of childbearing potential should be verified before starting this drug.
-If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.
-Human immunoglobulin G1 (IgG1) crosses the placenta; therefore, this drug has the potential to be transmitted from the mother to the developing fetus.
-Patients of childbearing potential should be advised to use effective contraception during therapy and for 3 months after the last dose.
-Advise males not to donate or store semen and to use effective contraception during treatment and for 3 months after the last dose.
-Patients should inform their healthcare provider if they are pregnant or plan to become pregnant.

Animal studies have not been reported; however, based on its mechanism of actions, this drug can cause fetal harm or developmental anomalies. Administration of epidermal growth factor receptor (EGFR) and mesenchymal-epidermal transition (MET) inhibitors in Animal studies have not been reported; however, based on its mechanism of actions, this drug can cause fetal harm or developmental anomalies. Administration of other epidermal growth factor receptor (EGFR) and mesenchymal-epidermal transition (MET) inhibitors in pregnant animals resulted in an increased incidence of impaired embryofetal development, embryolethality, and abortion. In mice, EGFR is very important in reproductive and developmental processes (including blastocyst implantation, placental development, and embryofetal/postnatal survival and development). Reduction/elimination of embryofetal or maternal EGFR signaling can prevent implantation, cause embryofetal loss during gestation (through effects on placental development) and cause developmental anomalies and early death in surviving fetuses. Adverse developmental outcomes were observed in multiple organs in embryos/neonates of mice with disrupted EGFR signaling. Similarly, knock out of MET or its ligand HGF (hepatocyte growth factor) was embryonic lethal due to severe defects in placental development, and fetuses displayed defects in muscle development in multiple organs. There are no controlled data in human pregnancy.

AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Amivantamab Breastfeeding Warnings

Breastfeeding is not recommended during use of this drug and for 3 months after the last dose.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments:
-No information is available on the clinical use of this drug during breastfeeding.
-The effects in the nursing infant are unknown; there is the potential for serious adverse reactions.

Since this drug is a large protein molecule (molecular weight about 148 kilodaltons), the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract; absorption by the infant is probably minimal.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer